Advice
Following an abbreviated submission
methotrexate injection 10mg/ml, (Metoject®) is accepted for use in NHS Scotland for the treatment of severe active rheumatoid arthritis in adult patients where treatment with disease modifying drugs (DMARD) is indicated.
For patients in whom parenteral methotrexate is appropriate, this is the first licensed parenteral formulation for this indication.
Download detailed advice29KB (PDF)
Medicine details
- Medicine name:
- methotrexate injection 10mg/ml, (Metoject)
- SMC ID:
- 332/06
- Indication:
- Severe active rheumatoid arthritis
- Pharmaceutical company
- Medac UK
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 11 December 2006